Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer
{{output}}
Background: Despite treatment advances in newly diagnosed advanced stage ovarian cancer (aOC), improved outcomes are needed. Patients and methods: ... ...
